Skip To Main Content
David-Dan Nguyen on Muck Rack

David-Dan Nguyen

As seen in: Wiley Online Library, BMJ Oncology, MDPI, JAMA (The Journal of the American Medical Association), JAMA Network, JAMA: Journal of the American Medical Association, Journal of The American Academy of Dermatology (JAAD), European Urology, Canadian Urological Association Journal, Urology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David-Dan

Contact David-Dan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The CUAJ trainee peer-reviewer training program

|
By David-Dan Nguyen, Adriana Modica, Andrew MacNeily
| Canadian Urological Association Journal Verified
Authors David-Dan Nguyen University of Toronto Adriana Modica CUA Andrew E.
Open in Who Shared Issue with article?

Reply to J.H. Kim and Y.S. Shin's Letter to the Editor re: Re: Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer–specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trial

|
By Temerty Faculty, David-Dan Nguyen, Borna Tadayon Najafabadi, Lauren Lin, Jethro C.C. Kwong, Girish Kulkarni
| European Urology Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Nguyen DD, Najafabadi BT, Lin L, et al. Effect of prostate cancer screening with prostate-specific antigen testing on long-term prostate cancer-specific mortality: a systematic review and meta-analysis of randomized controlled trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.04.005. 2. Shoag, J.E. ∙ Mittal, S. ∙ Hu, J.C. Reevaluating PSA testing rates in the PLCO trial N Engl J Med. 2016; 374:1795-1796 3.
Open in Who Shared Issue with article?

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma

|
By Eusebio Luna Velasquez, Renil S. Titus, David-Dan Nguyen, Carlos Riveros, Aly-Khan A. Lalani, Dharam Kaushik, P. Sonpavde, Petros Grivas, Christopher Wallis, Raj Satkunasivam
| JAMA Network Verified
Supplement 1. eTable 1. Diagnostic, Staging, and Treatment Codes for Cohort Identification in Metastatic Urothelial Carcinoma eTable 2. Adverse Event Definitions by Corresponding Diagnosis Codes eFigure 1. Flow Diagram of Patient Selection for Analysis of First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin in Metastatic Urothelial Carcinoma eFigure 2.
Open in Who Shared Issue with article?
See all 49 articles